Family reflections: pediatric aplastic anemia research; a parent perspective

Travis Georgieff

DOI: https://doi.org/10.1038/s41390-024-03498-5

IF: 3.953

2024-10-09

Pediatric Research

Abstract:The biggest and most challenging issue facing families of pediatric Aplastic Anemia patients is choosing the appropriate frontline treatment. In our experience, the standard guidelines followed by Hematologists is to heavily favor immunosuppressive therapy in the absence of a matched-sibling donor. This approach is supported by long-standing research, but it may not appropriately weigh and consider the latest advancements in bone marrow transplant regiments and post-transplant therapies. When our family was deciding on a treatment plan, there were surprisingly few research articles that advocated unrelated-donor transplants as a first-line therapy. Further, the research we could find was conducted on small cohorts over limited time horizons. We arrived at our decision for upfront transplant after consulting a number of expert researchers, immunologists, and bone marrow transplant specialists. Much of their recommendations were based on clinical experience and observations, not published and reviewed medical research. Unfortunately, many families of pediatric Aplastic Anemia patients lack either the resources or proactiveness to seek out such medical opinions. Thankfully, there has been a number of recent research efforts dedicated to comparing and studying first-line non-sibling donor treatment options for pediatric Aplastic Anemia patients. However, there should be even more resources dedicated to clinical trials that study large-scale and long-term pediatric for Aplastic Anemia first-line treatments. We would like updated data comparing the outcomes of unrelated, mismatched, and haploidentical donor transplants against immunosuppressive therapy. In particular, an updated view on the risks of relapse and clonal evolution of immunosuppressive therapy against the conditioning and post-transplant complications among the various transplant types would be beneficial. Such research will help both clinicians and parents to make an informed decision on patient care. It will also hopefully support an update to the standard of care guidelines for upfront treatments to consider additional transplant options. Second, we believe that pediatric Aplastic Anemia research resources should continue to be directed toward increasing the availability, effectiveness, and safety of alternative donor transplant programs. Unfortunately, there is still a significant underrepresentation of non-white ethnicities on national transplant registries. This leads to inequitable treatment options and unfavorable outcomes for many pediatric Aplastic Anemia patients. One of the most effective ways to bridge this gap is to continue to focus research on alternative donor options such as haploidentical and mismatched unrelated donor transplants. We strongly believe that every child should have a transplant option and are extremely grateful for the amount of research that has occurred in this segment within the past few years. We support the continued advancement of non-traditional transplant therapies with an emphasis on reducing toxicity, improving outcomes, and increasing access for all.

pediatrics